1143 related articles for article (PubMed ID: 31647023)
1. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
Liang B; Hu X; Ding Y; Liu M
J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
5. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
Morrissey SM; Yan J
Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
[TBL] [Abstract][Full Text] [Related]
6. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
10. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
[TBL] [Abstract][Full Text] [Related]
12. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
14. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms Controlling PD-L1 Expression in Cancer.
Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
[TBL] [Abstract][Full Text] [Related]
18. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
[TBL] [Abstract][Full Text] [Related]
19. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
20. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
